Skip to main content

Rapid Micro Biosystems, Inc.

corporate_fare Company Profile

Rapid Micro Biosystems, Inc.

RPID·NASDAQ·Industrial Applications And Services·CIK 0001380106

RAPID MICRO BIOSYSTEMS, INC. is an innovative life sciences technology company that provides critical automation solutions for pharmaceutical manufacturing. The company focuses on transforming microbial quality control (MQC) within pharmaceutical production through fully automated systems. Its products are designed to protect complex bioprocessing workflows, leading to faster, safer, and higher capacity drug production. The company's flagship product is the Growth Direct platform, which automates and modernizes manual MQC testing workflows used in large pharmaceutical manufacturing operations globally. This platform aims to bring quality control to the manufacturing floor, offering faster results, greater accuracy, increased operational efficiency, improved compliance with data integrity regulations, and quicker decision-making for customers. The Growth Direct platform is described as the only fully automated, high-throughput, and secure MQC solution, developed with over 15 years of customer feedback. It addresses MQC challenges related to the increasing scale, complexity, and regulatory scrutiny faced by global pharmaceutical manufacturers. The platform provides robust and scalable automation to support the growing demand for therapeutic modalities such as biologics, cell and gene therapies, vaccines, and sterile injectables. The systems are designed to automate most daily MQC test volume in pharmaceutical manufacturing facilities and can be operated in networked fleets of multiple systems per facility or campus to scale with high-volume manufacturing.

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for RPID at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Rapid Micro Biosystems Exceeds Raised Guidance with Record Q4 and Full-Year 2025 Revenue Growth

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$33.59M
Net Income
-$47.12M
Diluted EPS
-$1.05
Op. Cash Flow
-$31.06M
Free Cash Flow
-$31.91M
Operating Income
-$47.39M
Cash & Equivalents
$20.03M
Total Debt
$18.9M
Debt / Equity
0.57×
Net Margin
-140.3%
Shares Outstanding
44.68M sh
Source: 10-K · filed 2026-03-12 · accession 0001380106-26-000034
$0.7348 -0.03% today
52-week range · as of 2026-11-19 $0.5801 – $4.94
Market cap
$37.37M
Volume
1.4M (1.6× avg)
3-mo avg 905.9K
Live data · 2026-11-22 03:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RPID - Filings & News (Page 2)

RPID
Jan 13, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $0.7348 info
Change: -$2.57 (-78%) info
Market Cap: $37.369M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets